Long-term Use and Safety of JAK Inhibitors and Evaluating Efficacy Outcomes in Atopic Dermatitis : Episode 1

Video

June 5, 2023

Standard of Care in AD

Author(s):

Christopher G. Bunick, MD, PhD

Christopher G. Bunick, MD, PhD, discusses what can be done to improve the standard of care for atopic dermatitis (AD).

EP: 1.Standard of Care in AD

EP: 2.Clinical Outcomes in AD Clinical Trials

EP: 3.EASI Scores in AD Treatment

EP: 4.NRS in AD Treatment

EP: 5.AD: Efficacy Outcomes

EP: 6.RAD 2023 AD Trial: Meta-Analysis Data

EP: 7.AD Clinical Approach: Switching Therapies

EP: 8.Topical and Systemic Treatments for AD

EP: 9.Pathophysiology of AD Treatments

EP: 10.Treatment Selection in AD

EP: 11.JAK Inhibitor Safety

EP: 12.AD Treatment: Upadacitinib

EP: 13.Switching Therapies in AD

Related Videos

Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD

Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD

ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis

Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis

Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.